All News

Sifting through the data that came out of Urology Times' recently released "State of the Specialty" survey, it's clear that the issues most concerning to urologists relate to the business side of practicing medicine.

In this interview, Lora Plaskon, MD, MS, discusses her all-female urology/urogynecology practice's origins, how it differs from mixed-gender practices, and how her unique model fits into today's economy.

Depending on your approach, pursuit of higher yield bonds may invite more risk, some of which may be hard to see or understand.

The latest products and services from Coloplast, Galt Medical (Theragenics Corp.), the Medical Group Management Association, SullivanLuallin, Accuray Inc., the Simon Foundation for Continence, Varian Medical Systems, FAIR Health, Patient Point, UroMed, Cure Medical, and Three Ten LLC.

In May 2012, the United States Preventive Services Task Force recommended against PSA testing in all men based upon a flawed analysis that overestimated the harms and underestimated the benefits of testing.

Exposure to a desert environment increases lithogenic risk, but the effect is the result of unanticipated changes in excretion of lithogenic material, according to a recent study.

One of the elements in the Patient Protection and Affordable Care Act that may affect urologists is the Physician Payment Sunshine Provision, which requires drug and medical device manufacturers to publicly report gifts and payments made to physicians and teaching hospitals beginning in 2013.

Insertion of a ureteral access sheath during retrograde intra-renal surgery may induce severe ureteric injuries, according to a prospective analysis of 136 patients undergoing procedures using ureteral access sheaths.

Medicare recently made it clear that you should be able to charge for procedures performed on two separate lesions, which are not contiguous, in the same organ.

Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.

If sacral neuromodulation has failed for your patient, look beyond the problem of lead position. Abnormal impedances are common and are frequently associated with revision, say researchers from Cleveland Clinic.

Findings from a retrospective review of patients undergoing single-stage bulbar urethroplasty with buccal mucosa suggest that neither dorsal nor ventral onlay of the graft is inherently superior.

Hospital volume is a key predictor of survival for patients with urothelial bladder cancer undergoing radical cystectomy and has a greater impact than surgeon volume, findings from a retrospective analysis suggest.

In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.

Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.

More than 84% of patients with interstitial cystitis (IC) have tried complementary and alternative medicine (CAM) therapies, including dietary changes and physical therapy, and 55% report that their physicians have recommended CAM, according to findings from a recently published survey.

The FDA has approved a broader indication for the advanced prostate cancer treatment abiraterone acetate (ZYTIGA).

The majority of patients undergoing robot-assisted laparoscopic prostatectomy surgery for localized prostate cancer do not regret their treatment decision, according to a recent study.

Percutaneous tibial nerve stimulation (PTNS) and sacral nerve stimulation (SNS) are safe and efficacious for the treatment of overactive bladder, although the former is much more cost effective, results of a recent study indicate.

Nearly all U.S. urology offices (95.4%) still accept Medicare and two-thirds accept Medicaid, according to a recent report that suggests acceptance rates among all medical offices may be declining.Overall, 83.6% of U.S. medical offices accept Medicare and 67% accept Medicaid, the study found.

A study of more than 33,000 outpatient male veterans suggests that a duration of antimicrobial treatment of more than 7 days for a urinary tract infection (UTI) does not reduce the risk of early or late recurrence compared to a shorter duration (7 days or less) of treatment.

An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.

Image-guided targeted biopsy can be used to diagnose prostate cancer, potentially offering a more accurate approach than traditional blind biopsy, according to a recently published study.

Urinary continence and sexual function scores are similar up to 2 years after robot-assisted and open radical prostatectomy, especially when the procedures are performed by skilled, high-volume surgeons, new research shows.

Ajay Singla, MD, has joined The University of Toledo Medical Center, Toledo, OH, and separately, David M. Barrett, MD, has been elected to the board of directors of ProUroCare Medical Inc. in Minneapolis.

Joseph E. Murray, MD, a surgeon and Nobel Prize winner who conducted the world?s first successful organ transplant, died Nov. 26 at age 93.

About half of physicians treating patients with advanced renal cell carcinoma (RCC) believe that working with a comprehensive care team is extremely beneficial in helping to effectively manage adverse events associated with newer targeted therapies, according to a recently released survey.

Isolated cryptorchidism is linked to a higher likelihood of testicular cancer development, say researchers from the United Kingdom.

AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.

In this interview, Laurence Klotz, MD, discusses his group's active surveillance protocol for men with favorable-risk prostate cancer, which men are candidates, how they are monitored, and triggers for active treatment.